Click here to learn about Academy events, publications and initiatives around COVID-19.

We are experiencing intermittent technical difficulties. At this time, you may not be able to log in, register for an event, or make a donation via the website. We appreciate your patience, and apologize for any inconvenience this may cause.

Our site is under planned maintenance. At this time, you will not be able to log in, register for an event, or make a donation via the website. We appreciate your patience, and apologize for any inconvenience this may cause.

Support The World's Smartest Network
×

Help the New York Academy of Sciences bring late-breaking scientific information about the COVID-19 pandemic to global audiences. Please make a tax-deductible gift today.

DONATE
This site uses cookies.
Learn more.

×

This website uses cookies. Some of the cookies we use are essential for parts of the website to operate while others offer you a better browsing experience. You give us your permission to use cookies, by continuing to use our website after you have received the cookie notification. To find out more about cookies on this website and how to change your cookie settings, see our Privacy policy and Terms of Use.

We encourage you to learn more about cookies on our site in our Privacy policy and Terms of Use.

Frontiers in Cancer Immunotherapy 2021

WEBINAR

Only

Frontiers in Cancer Immunotherapy 2021

Wednesday, May 12, 2021, 10:30 AM - Friday, May 14, 2021, 5:00 PM EDT

Virtual Symposium

Presented By

Cancer Discussion Group

The New York Academy of Sciences

 

In the decade since the approval of the first checkpoint inhibitor, immunotherapy has shifted the paradigm for cancer treatment, delivering effective and durable responses for numerous patients. During that time, combination therapies, adoptive cell therapies, and cancer vaccines have further expanded the impact of immunotherapy.  Nonetheless, challenges remain in understanding why some tumor types are refractive to immunotherapy and how to better predict patient responses to treatment.  This three-day conference will convene experts in immuno-oncology to discuss the latest research in the field. Topics under consideration will include how insights from the immune response to infection can inform our understanding of cancer immunotherapy, the COVID-19/Immuno-oncology interface, advances in multiple myeloma, cytokines, novel checkpoints and more.

Registration

Member
$90
Nonmember Academia, Faculty, etc.
$195
Nonmember Corporate, Other
$255
Nonmember Not for Profit
$195
Nonmember Student, Undergrad, Grad, Fellow
$135
Member Student, Post-Doc, Fellow
$45
Deadline:
0
days
left

Keynote Speaker

Irving Weissman, MD
Irving Weissman, MD

Stanford University

Speakers

Paolo Ascierto, MD
Paolo Ascierto, MD

Istituto Nazionale Tumori IRCCS Fondazione Pascale, Napoli

Juliet Barker
Juliet Barker, MBBS

Memorial Sloan Kettering Cancer Center

Chiara Bonini
Chiara Bonini, MD

IRCCS Ospedale San Raffaele

Adelheid Cerwenka
Adelheid Cerwenka, PhD

Heidelberg University

George Coukos
George Coukos, MD, PhD

University of Lausanne

Kristen M. Hege, MD
Kristen M. Hege, MD

Bristol Myers Squibb

Katherine Hsu
Katherine Hsu, MD, PhD

Memorial Sloan Kettering Cancer Center

Eric L Smith
Eric Smith, MD, PhD

Dana Farber Cancer Institute

Ann Leen
Ann Leen, PhD

Baylor College of Medicine

Jeffrey Miller
Jeffrey Miller, MD

University of Minnesota

Richard O'Reilly
Richard O'Reilly, MD

Memorial Sloan Kettering Cancer Center

Charles Swanton
Charles Swanton, FRS

The Francis Crick Institute

Harlan Robins
Harlan Robins, PhD

Adaptive Biotechnologies

Jaume Pons
Jaume Pons, PhD

ALX Oncology

Bob Uger
Bob Uger, PhD

Trillium Therapeutics

John Wherry, PhD
John Wherry, PhD

University of Pennsylvania

Tahamtan Ahmadi, MD, PhD
Tahamtan Ahmadi, MD, PhD

Genmab

Shannon Turley, PhD
Shannon Turley, PhD

Genentech

Scientific Organizing Committee

Chris Boshoff, MD, PhD
Chris Boshoff, MD, PhD

Pfizer

Renier Brentjens, MD, PhD
Renier Brentjens, MD, PhD

Memorial Sloan Kettering Cancer Center

Padmanee Sharma, MD, PhD
Padmanee Sharma, MD, PhD

MD Anderson Cancer Center

George Zavoico, PhD
George Zavoico, PhD

Cue Biopharma

Sara Donnelly, PhD
Sara Donnelly, PhD

The New York Academy of Sciences

Sonya Dougal, PhD
Sonya Dougal, PhD

The New York Academy of Sciences

Barbara Knappmeyer, PhD
Barbara Knappmeyer, PhD

The New York Academy of Sciences


Wednesday

May 12, 2021

10:30 AM

Introduction and Welcome Remarks

Session 1: Viral Immunology and COVID-19

10:40 AM

Opening Keynote: TBD

11:25 AM

The Interface Between COVID-19 and Cancer Immunotherapy

Speaker

Ben Greenbaum, PhD
Memorial Sloan Kettering Cancer Center
12:05 PM

Management of Melanoma Patients During the COVID-19 Pandemic

Speaker

Paolo Ascierto, MD
National Tumor Institute Fondazione G. Pascale, Naples
12:35 PM

Lunch Break

1:05 PM

Virtual Poster Session 1

Session 2: Short Talks

2:00 PM

Lifileucel (LN-144), a Cryopreserved Autologous Tumor Infiltrating Lymphocyte (TIL) Therapy in Patients with Advanced (Unresectable or Metastatic) Melanoma: Median Duration of Response Not Reached at 28 Month of Study Follow-up

Speaker

Maria Fardis, PhD
Iovance Biotherapeutics
2:15 PM

Targeting Thrombospondin-1/CD47 Signaling Potentiates Anti-Tumor Immune Responses by Modulation of Cellular Bioenergetics

Speaker

Elizabeth Stirling, MS
Wake Forest School of Medicine

Session 3: Immune Responses and Virus Specific T Cells

2:30 PM

Immune Responses to COVID-19

Speaker

John Wherry, PhD
University of Pennsylvania
3:00 PM

Moving Towards Personalized T Cell Therapy

Speaker

Harlan Robins, PhD
Adaptive Biotechnologies
3:30 PM

T Cell Therapy for Viruses

Speaker

Ann Leen, PhD
Baylor College of Medicine
4:00 PM

Break

4:10 PM

Genetically Engineering Virus Specific T Cells

Speaker

Richard O’Reilly, MD
Memorial Sloan Kettering Cancer Center

Session 4: Neoantigens and Cancer Vaccines

4:40 PM

Cancer Vaccines, Dendritic Cells, and Antigen Presentation

Speaker

Nina Bhardwaj, MD, PhD
Icahn School of Medicine at Mount Sinai
5:10 PM

Adjourn Day 1

Thursday

May 13, 2021

10:30 AM

Welcome Back Remarks

Session 5: Cytokines

10:35 AM

Cell Therapies and Cytokines

Speaker

George Coukos, MD, PhD
University of Lausanne
11:05 AM

TNF Alpha and the Tumor Microenvironment

Speaker

Fran Balkwill, OBE, FMedSci
Barts Cancer Institute, Queen Mary University of London
11:35 AM

Break

11:45 AM

Harnessing NK Cells Against Cancer Through IL-15 Pathway Activation

Speaker

Willem Overwijk, PhD
Nektar Therapeutics
12:15 PM

TGF-Beta

Speaker

Shannon Turley, PhD
Genentech
12:45 PM

Lunch Break

Session 6: CD47 and SIRP Alpha

1:15 PM

Keynote: The Potential of CD47 as a Cancer Therapeutic

Speaker

Irving Weissman, MD
Stanford University
2:00 PM

CD47 Blockade

Speaker

Jaume Pons, PhD
ALX Oncology
2:30 PM

CAR-T Cells Targeting SIRP Alpha

Speaker

Bob Uger, PhD
Trillium Therapeutics
3:00 PM

Break

Session 7: RECIST / iRECIST

3:10 PM

RECIST / iRECIST

Speakers

Moderator: TBA
Sara Pai, MD, PhD
Harvard Medical School, Massachusetts General Hospital
Marc Theoret, MD
US Food and Drug Administration (FDA)
Priya Bhosale, MD
MD Anderson Cancer Center

Session 8: Multiple Myeloma

3:40 PM

Targeting CD38

Speaker

Tahamtan Ahmadi, MD, PhD
Genmab
4:10 PM

BCMA Directed Cell Therapies for Multiple Myeloma

Speaker

Kristin M. Hege, MD
Bristol Myers Squibb

B-cell maturation antigen (BCMA) is a member of the tumor necrosis factor superfamily that has restricted expression on malignant and normal plasma cells making it a high priority target for novel multiple myeloma therapies. Numerous therapeutic approaches targeting BCMA are in clinical development, including chimeric antigen receptor (CAR) T cells, bispecific T cell engagers (TCE) and antibody drug conjugates (ADC). Idecabtagene vicleucel (ide-cel) is a BCMA CAR T cell therapy that has demonstrated a high frequency of tumor responses, including complete responses, in advanced myeloma patients with low rates of grade 3/4 cytokine release syndrome (CRS) and neurotoxicity (NT) (Raje N, New Engl J Med 2019, Munshi N, N Engl J Med 2021). FDA approval was granted for ide-cel in March 2021. Product and treatment related correlates of durable response and progression have been identified; BCMA antigen escape has been reported, but is rare. bb21217, a next-generation BCMA CAR T cell therapy contains the same CAR construct as ide-cel, but uses ex vivo culture in the presence of a PI3-kinase inhibitor to enrich the final product with memory-like T cells. NEX-T BCMA is another next generation BCMA-targeted CAR T cell therapy that has entered the clinic. T cell engaging bispecific antibodies, while not a cellular therapy, offer another approach to driving T cell mediated BCMA-targeted tumor killing. Taken together these data support the benefit of BCMA targeted, T cell activating immunotherapies for the treatment of advanced myeloma.

4:40 PM

GPRC5D Target

Speaker

Eric Smith, MD, PhD
Dana-Farber Cancer Institute
5:10 PM

Adjourn Day 2

Friday

May 14, 2021

10:30 AM

Welcome Back Remarks

Session 9: NK Cells

10:35 AM

Single Cell Sequencing of Tumor Infiltrating NK Cells

Speaker

Adelheid Cerwenka, PhD
Heidelberg University
11:05 AM

NK Cell Reactivity and Haplo NK Infusions

Speaker

Katharine C. Hsu, MD, PhD
Memorial Sloan Kettering Cancer Center
11:35 AM

Break

11:45 AM

NK Cell Therapy: Targeting And Off-The-Shelf Strategies

Speaker

Jeffrey Miller, MD
University of Minnesota Medical School
12:15 PM

Neoadjuvant Immune Checkpoint Blockade: A Window into Treatment Response and Primary Resistance

Speaker

Suzanne L. Topalian, MD
Johns Hopkins School of Medicine
12:45 PM

Lunch Break

1:15 PM

Virtual Poster Session 2

Session 10: Short Talks

2:00 PM

Discovery of a Naturally Occurring Pluripotent Stem Cell Population in Human Peripheral Blood – Far-reaching Positive Consequences in Adoptive Cell Immunotherapy

Speaker

Vasilis Paspaliaris, PhD
Tithon Biotech
2:15 PM

Notch Pathway Activation Drives Immune Evasion in Hepatocellular Carcinoma

Speaker

Katherine E. Lindblad, BS
Icahn School of Medicine at Mount Sinai

Session 11: Hematopoietic Cell Transplant

2:30 PM

Unrelated Donor Transplant

Speaker

Bronwen Shaw MD, PhD
Medical College of Wisconsin
3:00 PM

Haploidentical Transplant

Speaker

Chiara Bonini, MD
Università Vita-Salute San Raffaele, Milan
3:30 PM

Break

3:40 PM

Umbilical Cord Blood as Source of Stem Cells

Speaker

Juliet N. Barker, MBBS
Memorial Sloan Kettering Cancer Center

Session 12: Tumor Evolution

4:10 PM

Tumor Evolution

Speaker

Charles Swanton, PhD
The Francis Crick Institute, UK
4:40 PM

Keynote: Next Frontiers in Cancer Immunotherapy

Speaker

Crystal Mackall, MD
Stanford University
5:25 PM

Conference Adjourns